Plain-English translation of NCT07488975 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This trial is testing a treatment called Pasteurized Akkermansia muciniphila (pAKK_LWHK0003), which is a type of beneficial bacteria that has been specially prepared and made inactive. Researchers want to see if taking this medication as a daily capsule for 4 months can help reduce fat in the liver and improve liver health in people with metabolic dysfunction-associated steatotic liver disease. The study will also carefully monitor how safe this treatment is.
Fatty liver disease caused by metabolic problems is becoming more common, and there are limited treatment options available. This trial explores whether this microbial-based approach could offer a new way to help people reduce liver fat and improve their overall liver function.
You would take one capsule of the medication (or placebo) by mouth each day for 120 days. You'll be randomly assigned to receive either a low, medium, or high dose of the treatment, or a placebo (inactive capsule) โ meaning you won't know which you're getting. During the trial, you'll have screening visits and follow-up appointments where doctors will check your liver health and make sure the treatment is safe for you.
AI-generated summary from trial data ยท Aug 30, 2026 ยท Not medical advice
Taiwan